Slovenian drugmaker Krka Q1 profit jumps by 42% as sales rise

Slovenian generic drugs producer Krka made a group net profit of 70.3 million euros ($78.4 million) in the first quarter of 2019 versus 49.4 million euros in the same period last year, Krka said in a statement on Thursday.

Updates with details, quote

LJUBLJANA, May 23 (Reuters) - Slovenian generic drugs producer Krka KRKG.LJ made a group net profit of 70.3 million euros ($78.4 million) in the first quarter of 2019 versus 49.4 million euros in the same period last year, Krka said in a statement on Thursday.

It said sales rose to 378.5 million euros, up from 338 million a year ago.

Sales in Eastern Europe, Krka's largest market, rose by 15%, while sales in Western Europe were 14% higher.

Krka also confirmed its goals for 2019, which were originally revealed in November, according to which profit is expected to reach at least 172 million euros - on a par with last year's level.

Sales are seen rising to 1.4 billion euros from 1.3 billion last year.

"The management will strive to exceed these goals," the company said in a statement, giving no further details.

Krka is Slovenia's largest listed company with a market capitalisation of 1.9 billion euros.

($1 = 0.8969 euros)

(Reporting by Marja Novak; Editing by Mark Potter)

((Marja.Novak@thomsonreuters.com; +386-1-5058805, Reuters Messaging: marja.novak.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More